country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-183185

Copy Link Print Information

BZ-30

BZ-30 is an orally active broad-spectrum SARS-CoV-2 inhibitor. BZ-30 acts on the early stage of the viral life cycle, can partially inhibit the endosomal entry process and reduce viral replication levels. BZ-30 reduces viral load, improves pulmonary pathological conditions, and decreases the lung-to-body weight ratio in hamster models challenged with SARS-CoV-2. BZ-30 can be used for research related to COVID-19.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No.: 3028405-31-1
화학식: C₁₄H₁₃F₆N₃
분자량:337.26

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

BZ-30 Chemical Structure

CAS No.: 3028405-31-1

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

In Vitro

BZ-30 (0.15-5 μM) reduces viral RNA levels by ≥99% in wild-type SARS-CoV-2-infected Vero E6 cells at the concentration of 5 μM, and exhibits dose-dependent antiviral activity^[1].
BZ-30 (24 h) potently inhibits the effective replication of wild-type SARS-CoV-2 in Vero E6 cells, with an IC₅₀ of 0.65 μM^[1].
BZ-30 (24 h) acts as a broad-spectrum inhibitor of SARS-CoV-2 variants of concern in Vero E6 cells, with IC₅₀ values ranging from 0.51 μM (Beta variant) to 12.37 μM (Omicron variant)^[1].
BZ-30 can partially inhibit the endosomal entry of SARS-CoV-2 pseudovirus; its inhibitory effect is stronger in HEK293-ACE2 cells (up to 75%) compared with the 50% inhibition rate observed in HEK293-ACE2/TMPRSS2 cells^[1].
BZ-30 (0-24 h) acts on the early stage of the wild-type SARS-CoV-2 life cycle in Vero E6 cells, and inhibits viral replication when administered within 2 h post-infection^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	T_max	C_max	AUC_0-last	AUC_0-∞	Bioavailability	T_1/2	V_d	CL
Mice^[1]	5 mg/kg	i.v.	/	/	711.9 nM·h	877.6 nM·h	/	3.9 h	8.43 L/kg	1.89 L/h/kg
Mice^[1]	10 mg/kg	p.o.	0.5 h	5003.8 nM	1759.4 nM·h	3029.1 nM·h	100 %	/	/	/

In Vivo

BZ-30 (15 mg/kg; i.p.; twice daily; 4 days starting 8 hours post-infection) reduces SARS-CoV-2 viral load by 64% and improves lung pathology in SARS-CoV-2-challenged Syrian golden hamsters^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Syrian Golden Hamsters (female, 6-8 weeks old, intranasally inoculated with 10⁵ PFU of SARS-CoV-2)^[1]
Dosage:

15 mg/kg
Administration:

i.p.; twice daily; 4 days (starting 8 h post-infection)
Result:

Reduced viral load by log₁₀ 0.44 TCID₅₀ per mg lung, corresponding to a 64% reduction in viral load.
Significantly reduced the lung-to-body weight ratio.
Maintained body weight comparable to the positive control remdesivir.
Lowered the cumulative histopathological lung score from 14 to 3.
Showed minimal alveolar and epithelial cell degeneration, with only occasional peri-vascular and peri-bronchiolar focal inflammatory cell infiltration.

Chemical Information

CAS No. 3028405-31-1
분자량 337.26
화학식 C₁₄H₁₃F₆N₃
SMILES

CC1(CCC1)NC2=NC3=C(C(F)(F)F)C=C(C(F)(F)F)C=C3N2
선적

Room temperature in continental US; may vary elsewhere.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Handling Instructions (2659 KB)

References

[1]. Kaur S, et al. Development of Benzimidazole-Based BZ-30 as an Orally Bioavailable Broad-Spectrum Inhibitor of SARS-CoV-2. J Med Chem. 2026;69(8):9537-9557. [Content Brief]

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

견적 받기 해외재고보유

Other size

견적 받기